When, where, and how does Alzheimer's disease start?

The Lancet Neurology

Volumn 11, Issue 12, 2012, Pages 1017-1018

  Fox, Nick ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; PRESENILIN 1;

ADULTHOOD; ALZHEIMER DISEASE; AMYLOID PLAQUE; AUTOSOMAL DOMINANT DISORDER; BRAIN ATROPHY; COGNITION; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE MUTATION; GRAY MATTER; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; LETTER; MENTAL PERFORMANCE; ONSET AGE; PATHOGENESIS; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL;

ALZHEIMER DISEASE; BRAIN; FEMALE; GENES, DOMINANT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; PRESENILIN-1;

EID: 84869106754     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(12)70256-9     Document Type: Letter

References (10)

1. Jack CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9:119-128.
2. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010, 9:1118-1127.
3. Golde TE, Schneider LS, Koo EH Anti-Aβ therapeutics in Alzheimer's disease: the need for a paradigm shift. Neuron 2011, 69:203-213.
4. Bapineuzumab phase 3: target engagement, but no benefit Alzheimer Research Forum, (accessed Oct 23, 2012). http://www.alzforum.org/new/detail.asp?id=3268.
5. Reiman EM, Langbaum JBS, Tariot PN Alzheimer's Prevention Initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med 2010, 4:3-14.
6. Bateman RJ, Aisen PS, De Strooper B, et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther 2011, 3:1-13.
7. Reiman EM, Quiroz YT, Fleisher AS, et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol 2012, published online Nov 6. http://dx.doi.org/10.1016/S1474-4422(12)70228-4.
8. Chavez-Gutierrez L, Bammens L, Benilova I, et al. The mechanism of gamma-secretase dysfunction in familial Alzheimer disease. EMBO J 2012, 31:2261-2274.
9. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012, 367:795-804.
10. Ridha BH, Barnes J, Bartlett JW, et al. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol 2006, 5:828-834.